I. Epidemiological profile

<table>
<thead>
<tr>
<th>Transmission</th>
<th>2015</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>High transmission (&gt;1 case per 1000 population)</td>
<td>4,280,000</td>
<td>3</td>
</tr>
<tr>
<td>Low transmission (&lt;1 cases per 1000 population)</td>
<td>12,400,000</td>
<td>8</td>
</tr>
<tr>
<td>Malaria-free (0 cases)</td>
<td>144,000,000</td>
<td>90</td>
</tr>
<tr>
<td>Total</td>
<td>161,000,000</td>
<td></td>
</tr>
</tbody>
</table>

II. Intervention policies and strategies

- **Single dose of primaquine is used as gametocidal medicine for:***
  - Treatment
  - Malaria diagnosis is free of charge in the public sector  Yes  2008
  - Uncomplicated Diagnosis
  - IPT
  - Larval control
  - Mass screening is undertaken  No  –
  - ACD of febrile cases at community level (pro-active)  Yes  2008
  - Surveillance
  - System for monitoring of adverse reactions to antimalarials exists  Yes  2008
  - G6PD test is a requirement before treatment with primaquine  No  –
  - ITNs/LLINs distributed to all age groups  Yes  2008

- **Intervention Policies/strategies Yes/No Adopted**
  - Total  161,000,000
  - Malaria-free (0 cases)  144,000,000  90
  - Low transmission (0–1 cases per 1000 population)  12,400,000  8
  - High transmission (>1 case per 1000 population)  4,280,000  3

- **Antimalaria treatment policy**
  - First-line treatment of unconfirmed malaria  –
  - First-line treatment of P. falciparum  QN+DX
  - Treatment failure of P. falciparum  QN+DX
  - Treatment of severe malaria  AS+AL
  - Treatment of P. vivax  CQ+PQ
  - Dosage of primaquine for radical treatment of P. vivax  0.25 mg/kg (14 days)
  - Type of RDT used  PF + all species (Combo)

- **Therapeutic efficacy tests (clinical and parasitological failure, %)**
  - Medicine  Year  Min  Median  Max  Follow-up  No. of studies  Species
  - AL  2006–2014  0  0  11.1  28 days  1  P. falciparum
  - QN+DX  2008–2010  0  0  1  28 days  1  P. falciparum
  - Deaths (all species)  Deaths (P. vivax)  Deaths (P. falciparum)  Deaths (other Plasmodium species)

- **Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)**
  - Year  Pyrethroid  DDT  Carbamate  Organophosphates  Species

III. Financing

- **Sources of financing**
  - Government budget  Global Fund  World Bank  USAID/PMI  WHO/UNICEF  Others

IV. Coverage

- **ITN and IRS coverage**
  - Population
  - At high risk protected with ITNs  %
  - Households with at least one ITN  %
  - At high risk protected with IRS  %

- **Cases tracked**
  - % Fever cases <5 seeking treatment at public HF (survey)  Reporting completeness

V. Impact

- **Confirmed malaria cases per 1000 and ABER**
  - Cases (%
  - ABER (%)

- **Malaria admissions and deaths**
  - Admissions
  - Deaths